Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model

Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model

Liver fibrosis occurring as an outcome of non-alcoholic steatohepatitis (NASH) can precede the development of cirrhosis. We investigated the effects of sorafenib in preventing liver fibrosis in a rodent model of NASH. Adult Sprague-Dawley rats were fed a choline-deficient high-fat diet and exposed t...

Full description

Bibliographic Details
Main Authors: J.T. Stefano, I.V.A. Pereira, M.M. Torres, P.M. Bida, A.M.M. Coelho, M.P. Xerfan, B. Cogliati, D.F. Barbeiro, D.F.C. Mazo, M.S. Kubrusly, L.A.C. D'Albuquerque, H.P. Souza, F.J. Carrilho, C.P. Oliveira
Format: Article
Language:English
Published: Associação Brasileira de Divulgação Científica 2015-05-01
Series:Brazilian Journal of Medical and Biological Research
Subjects:
NASH
Fibrosis
Mitochondrial dysfunction
Sorafenib
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2015000500408&lng=en&tlng=en

Internet

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2015000500408&lng=en&tlng=en

Similar Items